Latest Development News

Energy Transition Minerals has completed the acquisition of the Penouta tin, tantalum and niobium mine in Spain and is advancing the studies and permits needed for a potential restart. The company ended September with A$28.93 million in cash, equivalent to 8.4 quarters of funding at the latest reported spending rate.

TMK Energy has posted record quarterly gas production at its Mongolian pilot project while securing regulatory acceptance of a formal gas discovery. The milestone opens an appraisal pathway, but reserves, a production licence and longer-term funding remain unresolved.

Metgasco’s independently assessed 2P reserves have fallen to 6.2 PJe from 36.45 PJe, despite unchanged gas-in-place estimates at its Odin and Vali fields. The company says the change reflects current capital expenditure plans rather than a geological reduction, with 31.45 PJe now classified as 2C contingent resources.

ReNerve has reported its strongest quarter yet, with sales climbing to $584,000 as the medical device company expands across Asia-Pacific. The growth came alongside a secured funding drawdown, leaving the company with $1.62 million in cash but continued negative operating cash flow.

Viking Mines has confirmed significant tungsten mineralisation in all five assayed Linka Main holes, while advancing ore sorting, bulk sampling and processing plans in Nevada. The progress comes with no JORC resource yet defined and approximately 1.8 quarters of funding at current cash outflows.

Vintage Energy’s independently assessed 2P reserves have fallen to 12.4 PJe from 72.9 PJe, largely because Cooper Basin volumes were reclassified as contingent resources. The company says gas in place at Odin and Vali is effectively unchanged, but larger-scale development now depends on capital commitments and drilling results.

AdAlta is nearing two important development milestones for its EW-001 CAR-T therapy, with a US FDA pre-IND meeting scheduled for 4 November and Australian manufacturing runs expected before year-end. The progress comes with encouraging but early Chinese clinical data, while cash of A$0.65 million leaves limited room for delay.

Zeotech has begun an approximately 800-tonne commercial-scale AusPozz production trial while reporting independently replicated mining test results and a 92% average methane reduction in treated landfill cells. The September quarter also brought a non-binding VINCI Construction MOU, further Toondoon resource work and A$6.609 million in cash.

Stellar Resources has lifted its Heemskirk tin inventory to 115.3kt of contained tin, while post-quarter drilling has identified mineralisation outside the Severn resource that could connect with the high-grade Montana deposit. The company is now folding those possibilities into a prefeasibility study targeted for the first half of 2027.

Invex Therapeutics has agreed to acquire New Zealand biotech Rekover Therapeutics for shares and performance rights, adding a planned Phase 2a multiple sclerosis trial to its neurology portfolio. The transaction is paired with a $10 million placement, but would substantially expand the company’s share count and requires shareholder approval.

Western Mines Group has increased the Mulga Tank resource to 2.647 billion tonnes at 0.27% nickel, containing 7.2 million tonnes of nickel. The major exploration milestone now faces its more consequential test: whether a large, low-grade and unconstrained resource can support an economic mine.

Island Pharmaceuticals has secured approvals to use Galidesivir in Uganda’s Bundibugyo Ebola outbreak while advancing two complementary Marburg studies and expanding manufacturing. The progress comes with a sharper funding question: cash fell to A$7.83 million after quarterly operating outflows of A$4.93 million, leaving an estimated 1.6 quarters of funding.